REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics (NASDAQ:), Inc. (Soleno) (NASDAQ: SLNO) is a clinical-stage biopharmaceutical firm creating novel remedies for uncommon illnesses. Therapeutics, introduced right this moment that administration will current on the 2024 Cantor World Healthcare Convention on Tuesday, September 17, 2024 at 8:00 a.m. Jap Time.
A replay of the dwell audio webcast and presentation will probably be out there on the Buyers part of the Firm’s web site at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno focuses on the event and commercialization of novel therapies for the remedy of uncommon illnesses. The NDA for its lead drug candidate DCCR (diazoxide choline) extended-release tablets, a once-daily oral pill for the remedy of Prader-Willi syndrome (PWS), is at the moment beneath FDA overview and has been Get precedence overview. For extra data, please go to www.soleno.life.
Firm contact data:
Brian Wealthy
Life Sciences Consultants LLC
212-915-2578
Supply: Soleno Therapeutics
